We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-2.86%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.1B
AUM Growth
-$432M
Cap. Flow
-$290M
Cap. Flow %
-26.37%
Top 10 Hldgs %
65.53%
Holding
227
New
63
Increased
36
Reduced
51
Closed
66

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$19.5M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$7.96M
3
MNKD icon
MannKind Corp
MNKD
+$4.94M
4
ESPR
Esperion Therapeutics
ESPR
+$3.17M
5
BNBX
BNB PLUS CORP
BNBX
+$2.81M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$3.35M
2
BMY icon
Bristol-Myers Squibb
BMY
+$3.2M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$2.96M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$2.32M
5
HURA
TuHURA Biosciences
HURA
+$1.78M

Sector Composition

Rank Sector Weight
1 Healthcare 11.87%
2 Financials 0.19%
3 Industrials 0.07%
4 Consumer Staples 0.03%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVEO
151
CALL
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$34K ﹤0.01%
+12
New +$373
CSCI
152
CALL
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$33K ﹤0.01%
+1
New +$208
MNKD icon
153
CALL
MannKind Corp
MNKD
$1.21B
$27K ﹤0.01%
116
-1,611
-93% -$5.5K
OASM
154
DELISTED
Oasmia Pharmaceutical AB
OASM
$17K ﹤0.01%
19,000
– –
IMUC.WS
155
DELISTED
ImmunoCellular Therapeutics Ltd.
IMUC.WS
$16K ﹤0.01%
392,702
-27,401
-7% -$1.24K
CYTXW
156
DELISTED
Cytori Therapeutics Inc Warrant
CYTXW
$11K ﹤0.01%
1,028,634
-209,318
-17% -$5.57K
BIOA
157
DELISTED
BioAmber Inc.
BIOA
$9K ﹤0.01%
21,319
-3,159,654
-99% -$1.5M
ONSIZ
158
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$4K ﹤0.01%
199,193
-60,825
-23% -$3K
ONSIW
159
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$3K ﹤0.01%
89,644
-68,651
-43% -$4.64K
IMMU
160
PUT
DELISTED
Immunomedics Inc
IMMU
$2K ﹤0.01%
+305
New +$3.6K
ARMP icon
161
Armata Pharmaceuticals
ARMP
$175M
– –
-10,661
Closed -$136K
ATNM icon
162
Actinium Pharmaceuticals
ATNM
$26.2M
– –
-81,137
Closed -$1.4M
CDTX
163
DELISTED
Cidara Therapeutics
CDTX
– –
-3,215
Closed -$521K
CRDF icon
164
Cardiff Oncology
CRDF
$63.8M
– –
-23,469
Closed -$1.23M
CRMD icon
165
CorMedix
CRMD
$569M
– –
-129,791
Closed -$337K
CVM icon
166
CEL-SCI Corp
CVM
$20.3M
– –
-19,594
Closed -$976K
CYTK icon
167
CALL
Cytokinetics
CYTK
$10.8B
– –
-3,398
Closed -$4.93M
CYTK icon
168
PUT
Cytokinetics
CYTK
$10.8B
– –
-237
Closed -$344K
DBVT
169
CALL
DBV Technologies
DBVT
$798M
– –
-1,091
Closed -$46.3M
DBVT
170
PUT
DBV Technologies
DBVT
$798M
– –
-178
Closed -$7.57M
CHRN
171
ChronoScale Holdings
CHRN
$2.79B
– –
-3,122
Closed -$850K
FCEL icon
172
FuelCell Energy
FCEL
$1.56B
– –
-33
Closed -$22.9K
GEVO icon
173
Gevo
GEVO
$353M
– –
-11,241
Closed -$140K
IMNN icon
174
Imunon
IMNN
$6.43M
– –
-345
Closed -$101K
INSM icon
175
CALL
Insmed
INSM
$22.6B
– –
-1,375
Closed -$4.29M
5 6
7
8 9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sabby Management held 227 positions worth $1.1B, down 28% from $1.53B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management withdrew a net $290M in Q4 2017, closing 66 positions and reducing 51 holdings. Its most notable exit was GW Pharmaceuticals Plc American Depositary Shares, an estimated $3.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 7.3% a quarter earlier, followed by Financials and Industrials.

Against the trend, Sabby Management opened a new position in Odonate Therapeutics, Inc. Common Stock worth $20.6M.

  • Sabby Management's largest Q4 2017 buy was Odonate Therapeutics, Inc. Common Stock: 825,451 shares worth $20.6M.
  • Sabby Management added most to Esperion Therapeutics in Q4 2017, an estimated $3.17M increase.
  • Sabby Management's biggest Q4 2017 reduction was Bristol-Myers Squibb, cutting an estimated $3.2M.
  • Sabby Management fully exited GW Pharmaceuticals Plc American Depositary Shares in Q4 2017, selling an estimated $3.35M.
  • Sabby Management's ten largest holdings make up 66% of its $1.1B portfolio in Q4 2017.
  • Sabby Management opened 63 new positions and closed 66 in Q4 2017.
  • Sabby Management's portfolio value fell 28% quarter-over-quarter to $1.1B.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.